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Abstract
IgE was the last of the five immunoglobulin classes to be discovered and is the antibody that is
responsible for much of human type I allergic disease. This review summarizes recent developments
with respect to control of IgE synthesis with an emphasis on Th2 (T helper 2) control and regulation
using IgE Fc receptors.
Introduction and context
The primary biological function of IgE is to provide
immunity against multicellular parasitic pathogens such
as helminths. Large IgE responses are seen in both
humans and other mammals as a result of such
infections. In developed countries, where such diseases
are rare, IgE responses directed against innocuous
allergens result in type I allergic disease. Since IgE is the
only immunoglobulin class thought to be involved in
human type I allergy, methods to control IgE synthesis
represent a clear way to control this disease. This remains
a significant challenge. Indeed, the closest approach is
immunotherapy, which was initiated in the early 1900s.
Immunotherapy involves administering increasing doses
of allergen to achieve desensitization and/or tolerance.
Significant improvements in allergen purity have greatly
enhanced its effectiveness, especially when treating
patients with responses to only these well-characterized
allergens [1]. While the mechanism remains controver-
sial, neutralizing antibodies (IgG in nature) to the
allergen as well as tolerance induction are potentially
both involved.
Major recent advances
The development of therapies that would specifically
inhibit class switching to IgE would have a dramatic
impact on allergic disease. However, mechanisms for
isotype switching are usually common to other Ig classes
(see [2,3] for review). The discovery of the role of
activation-induced deaminase (AID) by the Honjo
laboratory [4] was a key event. Additionally, T-cell
help, long known to be critical for isotype switching,
comes from CD40-CD40L (CD40-CD40 ligand) inter-
action and specific cytokines. Patients who lack either
AID or CD40L are limited primarily to an IgM response
[5,6]. While other cytokines such as BAFF (B-cell
activating factor belonging to the tumor necrosis factor
family) and APRIL (a proliferation-inducing ligand) can
induce both T cell-independent and T cell-dependent
class switching to IgE (at least in vitro), current thought is
that CD40-CD40L and AID are required for significant in
vivo IgE production. B-cell activation via Toll-like
receptor 4 (TLR4) also effectively induces IgE class
switching. However, at least in mice [7], TLR4 stimula-
tion attenuates the mouse asthma model. One unique
feature of IgE class switching is the general necessity for T
helper 2 (Th2) differentiation. Since interleukin-4 (IL-4)
production is important not only for Th2 development
but also for isotype switching, blocking its activity
represents a clear strategy for IgE control. Clinical trials
were performed using a soluble form of the IL-4 receptor;
however, modest efficacy was achieved in asthma
treatment (discussed in [8]). Potential new directions
in cytokine therapy for allergic disease come from recent
studies with IL-21, IL-25, and IL-33 and thymic stromal
lymphopoietin (TSLP). Over 10 years ago, the Hodgkin
laboratory reported that isotype switching to IgG and IgE
required multiple cell divisions [9]. Up to five divisions
were required for IgG, and eight were required for
optimal IgE production. While the IgG data from this
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human IgE production required additional signals.
Adding IL-21 to the culture allowed our group to extend
the multiple division requirement for IgE production to
humans [11]. IL-21 is known to signal through STAT3
(signal transducer and activator of transcription 3), and
Avery et al. [12] demonstrated that B cells from patients
with loss-of-function mutations in STAT3 did not
respond to IL-21. Interestingly, mutations in STAT3 are
also associated with the autosomal dominant form of
HIES (hyper IgE syndrome) [13], a condition in which
patients have extremely elevated serum IgE levels,
recurrent eczema, and an increased risk for skin and
lung infections. IL-25 (also called IL-17E) has emerged as
another key regulator of the Th2 response. Overexpres-
sion of IL-25 results in enhanced IgE responses [14].
Recent evidence suggests that IL-33, a member of the IL-1
family, has a role in Th2-mediated disease (reviewed in
[15]). Blockade of the mouse IL-33 receptor results
in inhibition of antigen-specific IgE production, at least
in response to low antigen doses [16]. TSLP has been
shown to upregulate OX40L on dendritic cells. Blocking
the interaction with OX40 by neutralizing antibodies
resulted in decreased Th2 development and IgE produc-
tion [17]. Finally, g,d T cells can have both IgE-enhancing
and IgE-suppressing properties and recent evidence
indicates that the suppressing g,d T cells are important
in controlling the airway allergen response [18]. Because
these later studies were completed in rodent models,
current studies are needed to determine whether human
IgE production is regulated by similar mechanisms. Data
suggesting some involvement of IL-25 and IL-33 with
human Th2 development have already been reported
[19,20].
A second area of investigation regarding IgE control
involves the interaction of IgE with its two Fc receptors.
Studies focusing on high-affinity IgE receptor (FceRI) are
directed primarily toward blocking the FceR1/IgE inter-
action. The crystal structure of the FceRI/IgE complex is
known [21] and may ultimately lead to the development
of compounds that can block this interaction. At present,
such agents are not available, but a current treatment
approved by the US Food and Drug Administration for
severe asthma involves injecting a monoclonal anti-IgE
antibody (Xolair®, or omalizumab) that binds the
identical or closely associated region of IgE that interacts
with the FceRI [22,23]. This monoclonal antibody
effectively blocks IgE binding to the FceRI. Additionally,
extended therapy (due to the protection from degrada-
tion that IgE binding gives the FceRI) results in low FceRI
expression levels [24]. This treatment has shown good
efficacy. However, the primary disadvantages are the
expense and the form of administration. Since IgE
synthesis is not inhibited, the antibody injections need
to be repeated approximately every three weeks.
The second IgE receptor (FceRII or CD23) is expressed
primarily on B lymphocytes in mice and, since its
discovery, has been proposed to be a natural regulator of
IgE synthesis [25]. CD23 is upregulated by IL-4 and
stabilized on the cell surface by IgE binding. This
stabilization prevents cleavage from the cell surface by
the CD23 sheddase(s) [25]. Indeed, mice that lack CD23
exhibit some augmentation in their IgE response to
allergens but not helminth infection [26]. CD23
transgenic mice that overexpress the receptor on lym-
phocytes have greatly reduced IgE responses [27]. A
clinical trial using anti-CD23 (lumiliximab) directed
against the lectin part of the molecule resulted in a
reduction in serum IgE levels by approximately two-
thirds, but this was not sufficient to significantly
influence disease symptomology [28]. This anti-CD23
is thought to mimic IgE binding and stabilize CD23,
resulting in less cleavage by ADAM10 (a disintegrin and
metaloprotease 10). Use of this anti-CD23 in conjunc-
tion with the anti-IgE mentioned above remains to be
tested. Antibodies directed against the stalk region of the
molecule result in CD23 instability, significantly
enhanced CD23 cleavage, and enhanced IgE production
[29]. In addition, soluble CD23 trimer has been shown
to increase IgE production in the human in vitro culture
model [30]. These studies stimulated interest in identify-
ing the CD23 sheddase. In collaboration with the Blobel
laboratory, we recently identified the primary sheddase
as the metalloprotease ADAM10 [31]. This result was
confirmed by Lemieux et al. [32]. Recently, Jackson et al.
[33] reported that matrix metaloprotease 9 (MMP9) can
also act as a CD23 sheddase following TLR4 activation
with lipopolysaccharide. However, MMP9 deficiency is
associated with high IgE levels in mice [34], potentially
due to excess IL-4 production. We are currently
investigating whether ADAM10 may be a potential target
for controlling IgE production.
Future directions
New therapies that harness the natural regulator capacity
of CD23 (discussed above) or T-regulatory cells
(reviewed in [35]) are promising areas for future
investigation. Agents that influence the nervous system
have recently been shown to influence the mouse IgE
response [36,37], so this is also an area of future
investigation. Finally, the investigation of the innate
and adaptive immunity-associated cytokines discussed
above (IL-25, IL-33, and TSLP) for control of human IgE
responses will certainly be of interest. The goal of IgE
synthesis inhibition should give broad-spectrum type I
allergy control and thus remains a very worthy objective.
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